Sugi Predict

Sugi Predict / Compounds / SCHEMBL1124024

SCHEMBL1124024

SCHEMBL1124024

O=Cc1ccc(-c2cncnc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 4/20 0.52
▸ ATM Q13315 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ DRD1 P21728 1/20 0.42
▸ CYP2A6 P11509 3/20 0.41
▸ XDH P47989 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ALDH5A1 P51649 1/20 0.41
▸ ABAT P80404 1/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ KIF11 P52732 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5719996 0.90 ERN1 (0.45) ERN1ATMALDH1A1KDM4ESMN1; SMN2
SCHEMBL29042267 0.82 MKNK1 (0.43) ERN1ALDH1A1KDM4ESMN1; SMN2DRD1
SCHEMBL28672139 0.80 ALDH1A1 (0.54) ATMALDH1A1KDM4ESMN1; SMN2DRD1
SCHEMBL976904 0.80 CYP2A6 (0.58) ALDH1A1KDM4EDRD1CYP2A6HSD17B10
SCHEMBL6682176 0.80 ATM (0.72) ERN1ATMALDH1A1KDM4ESMN1; SMN2
SCHEMBL25288128 0.80 CYP2A6 (0.58) ALDH1A1KDM4EDRD1CYP2A6HSD17B10
SCHEMBL1666706 0.80 CYP2A6 (0.58) ALDH1A1KDM4EDRD1CYP2A6HSD17B10
SCHEMBL27335985 0.80 CYP2A6 (0.58) ALDH1A1KDM4EDRD1CYP2A6HSD17B10
SCHEMBL6653966 0.79 ALDH1A1 (0.48) ERN1ATMALDH1A1KDM4ECYP2A6
SCHEMBL6653970 0.79 ALDH1A1 (0.48) ERN1ATMALDH1A1KDM4ECYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189504-A1 BROAD - SPECTRUM ANTI VIRAL COMPOUNDS FOUNDATION FOR NEGLECTED DISEASE RESEARCH (IN) 2024-09-19 — — WO disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 — — US disclosed
EP-3974426-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS Indiana University Research and Technology Corporation (US) 2022-03-30 — — EP disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 — — US disclosed
EP-3349581-B1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2021-12-01 — — EP disclosed
EP-3349581-B1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2021-12-01 — — EP disclosed
CN-108347942-B Hepatitis B core protein modulators 组装生物科学股份有限公司 2021-09-03 — — CN disclosed
EP-1021410-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 2000-07-26 — — EP disclosed
CN-1259948-A 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds ABBOTT LAB (US) 2000-07-12 — — CN disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 — — WO disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 — — EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 — — EP disclosed
WO-1999019300-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 1999-04-22 — — WO disclosed
EP-0891355-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 — — EP disclosed
US-5854264-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1998-12-29 — — US disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
WO-1997036896-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 ERN1 1341/4885ATM 3527/4885ALDH1A1 4382/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ERN1 117/4885ATM 4536/4885ALDH1A1 4277/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 ERN1 117/4885ATM 4536/4885ALDH1A1 4277/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ERN1 117/4885ATM 4536/4885ALDH1A1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.